Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria.

Scientific reports - 21 Feb 2022

Andoni Tala, Wiggins Jennifer, Robinson Rachel, Charlton Ruth, Sandberg Michael, Eeles Rosalind

Abstract excerpt

Genetic testing for cancer predisposition has been curtailed by the cost of sequencing, and testing has been restricted by eligibility criteria. As the cost of sequencing decreases, the question of expanding multi-gene cancer panels to a broader population arises. We evaluated how many additional actionable genetic variants are returned by unrestricted panel testing in the private sector compared to those which...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to England

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Counseling

Share to Genetic Testing

Share to Germ-Line Mutation

Share to Incidence

Share to Neoplasms

Share to Risk Assessment

Source

Open in PubMed Open full text

Identifiers

PMID: 35190596
DOI: 10.1038/s41598-022-06376-4
PMCID: PMC8861039

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria.PMID 35190596Read ↗

Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group.Semantic proximity Read ↗

A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patientsSemantic proximity Read ↗

Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program.Semantic proximity Read ↗

Germline potential should not be overlooked for cancer variants identified in tumour-only somatic mutation testing.Semantic proximity Read ↗

Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients.Semantic proximity Read ↗

Mutation prevalence tables for hereditary cancer derived from multi-gene panel testingSemantic proximity Read ↗

The clinical utility and costs of whole-genome sequencing to detect cancer susceptibility variants—a multi-site prospective cohort studySemantic proximity Read ↗

Evaluation of a 27-gene inherited cancer panel across 630 consecutive patients referred for testing in a clinical diagnostic laboratorySemantic proximity Read ↗

Unrecognised actionability for breast cancer risk variants identified in a national-level review of Australian familial cancer centres.Semantic proximity Read ↗

Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening.Semantic proximity Read ↗

Genetic testing today.Semantic proximity Read ↗

Clinically significant germline pathogenic variants are missed by tumor genomic sequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.